<DOC>
	<DOCNO>NCT00076869</DOCNO>
	<brief_summary>Invasive aspergillosis type fungal infection typically identify sick patient ( example , patient cancer bone marrow organ transplant ) . This study seek enroll patient ( 16 year age old ) invasive aspergillosis infection ( involve organ deep tissue ) fail could tolerate standard antifungal therapy . Your doctor make determination base upon specific study criterion . Patients fulfill study criterion treat daily investigational drug another antifungal agent . The choice agent doctor . This investigational drug approve treatment invasive aspergillosis . The safety efficacy investigational drug , combination agent know .</brief_summary>
	<brief_title>MK0991 Combination With Standard Antifungal Agent ( ) Treatment Salvage Invasive Aspergillosis ( 0991-037 )</brief_title>
	<detailed_description>The duration treatment 12 month .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Patients must meet specific definition probable definite invasive aspergillosis consider fail intolerant standard antifungal therapy . The patient must least 16 year old woman childbearing potential , must negative serum urine pregnancy test sensitive 25 IU hCG prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Definite probable Invasive Aspergillosis either refractory intolerant prior antifungal treatment .</keyword>
</DOC>